RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19
18 Mars 2020 - 02:42PM
RECORDATI CONTRIBUTES TO SUPPORT
HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY
DUE TO COVID-19
Milan, 18 March 2020 – Recordati announces that
the Group has allocated € 5 million to contribute to the support of
hospitals and health facilities in their fight against the
epidemiologic emergency due to COVID-19.
To this end a number of initial interventions to
support the main health facilities in Lombardy, the region which is
currently mostly impacted by the epidemic, are under study and
involve the preparation of areas dedicated to intensive care
operations including all necessary equipment.
Furthermore, the Company is preparing to be able
to provide those medicines in its portfolio, which are particularly
useful for patients affected by COVID-19, free of charge.
“In this particularly serious moment for the
whole of the European population, and not only, Recordati is
actively present and committed to help doctors and patients and
contribute as much as possible to halt and resolve health emergency
situations in all health facilities in need” declared Andrea
Recordati, CEO.
Recordati, established in 1926,
is an international pharmaceutical group, listed on the Italian
Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271), with a total staff of more than 4,100, dedicated to
the research, development, manufacturing and marketing of
pharmaceuticals. Headquartered in Milan, Italy, Recordati has
operations throughout the whole of Europe, including Russia,
Turkey, North Africa, the United States of America, Canada, Mexico,
some South American countries, Japan and Australia. An
efficient field force of medical representatives promotes a wide
range of innovative pharmaceuticals, both proprietary and under
license, in a number of therapeutic areas including a specialized
business dedicated to treatments for rare diseases. Recordati is a
partner of choice for new product licenses for its territories.
Recordati is committed to the research and development of new
specialties with a focus on treatments for rare diseases.
Consolidated revenue for 2019 was € 1,481.8 million, operating
income was € 465.3 million and net income was € 368.9 million.
For further information:
Recordati website: www.recordati.com
Investor Relations
Media
Relations
Marianne
Tatschke
Studio Noris
Morano
(39)0248787393
(39)0276004736, (39)0276004745e-mail: investorelations@recordati.it
e-mail:
norismorano@studionorismorano.com
Statements contained in this release, other than
historical facts, are "forward-looking statements" (as such term is
defined in the Private Securities Litigation Reform Act of 1995).
These statements are based on currently available information, on
current best estimates, and on assumptions believed to be
reasonable. This information, these estimates and assumptions may
prove to be incomplete or erroneous, and involve numerous risks and
uncertainties, beyond the Company’s control. Hence, actual results
may differ materially from those expressed or implied by such
forward-looking statements. All mentions and descriptions of
Recordati products are intended solely as information on the
general nature of the company’s activities and are not intended to
indicate the advisability of administering any product in any
particular instance.
Recordati (BIT:REC)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Recordati (BIT:REC)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024